Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder

Human Pathology

Volumn 44, Issue 4, 2013, Pages 612-622

  Gonzalez Roibon, Nilda D ^a   Chaux, Alcides ^a   Al Hussain, Turki ^a   Osunkoya, Adeboye O ^b   Bezerra, Stephania Martins ^a   Hicks, Jessica ^a   Epstein, Jonathan I ^a   Netto, George J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; Mammalian target of rapamycin; Plasmacytoid urothelial carcinoma; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN S6;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; URINARY BLADDER PLASMACYTOID UROTHELIAL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GEORGIA; HUMANS; MALE; MARYLAND; MIDDLE AGED; PHOSPHORYLATION; PLASMA CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84875226280     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.07.009     Document Type: Article

References (35)

1. J.N. Eble, G. Sauter, J.I. Epstein, and I.A. Sesterhenn Pathology and Genetics: tumors of the urinary system and male genital organs WHO classification of tumors 2004 IARC Press Lyon
2. A.A. Sahin, M. Myhre, J.Y. Ro, N. Sneige, R.H. Dekmezian, and A.G. Ayala Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma Acta Cytol 35 1991 277 280
3. L.R. Zukerberg, N.L. Harris, and R.H. Young Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases Am J Surg Pathol 15 1991 569 576
4. A. Gaafar, M. Garmendia, and E. de Miguel Plasmacytoid urothelial carcinoma of the urinary bladder. A study of 7 cases Actas Urol Esp 32 2008 806 810
5. B. Keck, R. Stoehr, and S. Wach The plasmacytoid carcinoma of the bladder-rare variant of aggressive urothelial carcinoma Int J Cancer 129 2011 346 354
6. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
7. L. Schultz, R. Albadine, and J. Hicks Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
8. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
9. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
10. G. Viglietto, M.L. Motti, and A. Fusco Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization Cell Cycle 1 2002 394 400
11. M.A. Dominguez-Caceres, J.M. Garcia-Martinez, and A. Calcabrini Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells Oncogene 23 2004 7378 7390
12. K.T. Mai, P.C. Park, and H.M. Yazdi Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases Eur Urol 50 2006 1111 1114
13. H.M. Fritsche, M. Burger, S. Denzinger, W. Legal, P.J. Goebell, and A. Hartmann Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases J Urol 180 2008 1923 1927
14. P. Nigwekar, P. Tamboli, M.B. Amin, A.O. Osunkoya, D. Ben-Dor, and M.B. Amin Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases Am J Surg Pathol 33 2009 417 424
15. M.R. Raspollini, I. Sardi, and L. Giunti Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series Hum Pathol 42 2011 1149 1158
16. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
17. J. Coyne, and E. Sim Urothelial neoplasia with plasmacytoid morphology Histopathology 48 2006 200 201
18. C.B. Ching, and D.E. Hansel Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway Lab Invest 90 2010 1406 1414
19. M. Miyakawa, T. Tsushima, H. Murakami, K. Wakai, O. Isozaki, and K. Takano Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues Endocr J 50 2003 77 83
20. W. Feng, R.E. Brown, and C.D. Trung Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma Ann Clin Lab Sci 38 2008 195 209
21. T.R. Hartman, E. Nicolas, and A. Klein-Szanto The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis Oncogene 28 2009 1594 1604
22. L. Schultz, A. Chaux, and R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
23. A.J. Armstrong, G.J. Netto, and M.A. Rudek A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer Clin Cancer Res 16 2010 3057 3066
24. J.C. King, J. Xu, and J. Wongvipat Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis Nat Genet 41 2009 524 526
25. B.S. Carver, J. Tran, and A. Gopalan Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 2009 619 624
26. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
27. L.D. Harris, J. De La Cerda, and T. Tuziak Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray Mol Carcinog 47 2008 678 685
28. C.N. Qian, K.A. Furge, and J. Knol Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models Cancer Res 69 2009 8256 8264
29. F.M. Platt, C.D. Hurst, C.F. Taylor, W.M. Gregory, P. Harnden, and M.A. Knowles Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer Clin Cancer Res 15 2009 6008 6017
30. S. Bose, S. Chandran, J.M. Mirocha, and N. Bose The Akt pathway in human breast cancer: a tissue-array-based analysis Mod Pathol 19 2006 238 245
31. G.J. Netto Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 9 2011 41 51
32. D.A. Bradley, R. Dunn, and D. Nanus Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design Clin Genitourin Cancer 5 2007 460 463
33. J.J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata, and W. Kassouf Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer Cancer Biol Ther 8 2009 2339 2347
34. E. Seront, S. Rottey, and B. Sautois Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers Ann Oncol 2012 10.1093/annonc/mds057
35. E.V. Schmidt, M.J. Ravitz, L. Chen, and M. Lynch Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway Cell Cycle 8 2009 1344 1351